Apologies for my tardy post but the Scottish Medicines Consortium has mimicked the earlier NICE decision to approve Ibrutinib as a second line treatment. See extract from their April newsletter:
"Also accepted through the PACE process was ibrutinib (Imbruvica). Ibrutinib can be used to treat chronic lymphocytic leukaemia (CLL) in patients with disease that has relapsed after previous therapy. Through PACE, patient groups and clinicians highlighted that CLL, a rare, debilitating cancer of the blood, has a significant impact on patients and their families. Ibrutinib is an oral preparation that is better tolerated than currently available alternatives. It has been shown to delay progression of the disease with potential improvement in quality of life."
Health Canada approves Ibrutinib plus Rituximab for First Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
Suspending Ibrutinib 
Ibrutinib, Acalabrutinib, or Zanubrutinib 
Ibrutinib Slow but steady foreward movement.
